RedHill Biopharma (NASDAQ:RDHL) has replaced its existing 2015 co-commercialization agreement with Daiichi Sankyo (OTCPK:DSKYF) for Movantik (naloxegol) with a new royalty-bearing agreement, under April 2020 acquisition agreement with AstraZeneca (NYSE:AZN).
Under the terms of the new agreement, RedHill will bear all responsibilities and costs for commercializing Movantik in the U.S. and will pay Daiichi a mid-teen royalty, in addition to three lump sum payments.
Additionally, the companies also entered a subscription agreement under which Daiichi received 283,387 ADSs of RedHill as a partial consideration in relation to Movantik.
RDHL acquired the global rights, excluding Europe, Canada and Israel, to Movantik for the treatment of opioid induced constipation from AstraZeneca in April 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.